gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Elotuzumab’s Fc engages CD16A on NK cells to trigger ADCC against SLAMF7-positive tumor cells; CD16A-expressing cells act as effectors and are not killed.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc-mediated ADCC; binding affinity influenced by FCGR3A V158F polymorphism
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06163040
disease_id_num_tar_ref
1949
drug_id_num_tar_ref
5219